|

Relacorilant 150 mg once daily (QD) Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: CORT125134

Scottsdale, Arizona1 trial

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Site 02

Phase 2

Palo Alto, California1 trial

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

150

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.